The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Guidelines recommend maintenance TKI monotherapy following remission, though data are limited regarding outcomes following TKI discontinuation. Researchers sought to evaluate long-term outcomes in this scenario.
Although technically not a cancer, its natural history, treatment toxicity, and long-term complications have long demanded the same level of therapeutic urgency and innovation seen in malignant hematology. The rarity of SAA has never diminished the intensity of research in this field; rather, its curability has driven decades of progress aimed at restoring hematopoiesis efficiently, safely, and durably.
The approval was supported by results from the global randomized phase 3 VERIFY trial involving 293 patients, which showed that patients receiving rusfertide demonstrated a higher clinical response rate, including maintained hematocrit control and reduced phlebotomy requirements, compared to placebo alongside standard care.
In this SOHO Insider video interview, Elias Jabbour, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer
The investigators, led by Ryan C Lynch, MD, of Fred Hutchinson Cancer Center in Seattle, Washington, published their findings in the Journal of Clinical Oncology.
The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
